-
FDA Drug Approvals Q1 2024
24 Apr 2024 15:11 GMT
… liposomal) – Indicated in combination with oxaliplatin, fluorouracil, and leucovorin for first … approval for non-small cell lung cancer (initially accelerated approval)
Wyost (denosumab …
-
Acupuncture in Multiple Myeloma Peripheral Neuropathy: A Systematic Review
24 Apr 2024 12:42 GMT
… diabetic PN and paclitaxel- and oxaliplatin- induced PN,9,10 suggesting … interest in support services among lung cancer patients. Lung Cancer. 2013;82(1):162 …
-
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
07 Feb 2024 12:27 GMT
… cancers to date, including lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816-neoadjuvant non-small cell lung cancer, …
-
The Relationship Between the Expression of circFAT1 and Immune Cell in Patients with Non-Small Cell Lung Cancer
31 Oct 2023 03:22 GMT
… small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases. … in non-small cell lung cancer: gene regulation, impact … in non-small cell lung cancer: mechanistic insights and therapeutic … (SKA1) axis regulates oxaliplatin resistance in breast cancer …
-
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
17 Oct 2023 20:05 GMT
… tumor types, including lung cancer, bladder cancer, esophageal … distant metastases.
About Lung Cancer
Lung cancer is the leading … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
17 Oct 2023 19:36 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
22 Sep 2023 11:10 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
11 Sep 2023 11:28 GMT
… L1 ≥1%.
About Lung Cancer
Lung cancer is the leading cause … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … with a fluoropyrimidine, oxaliplatin, and irinotecan. This … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Pseudoprogression Disease in a Patient with Small Cell Lung Cancer on Immune Checkpoint Inhibitor Therapy
31 Aug 2023 19:49 GMT
… Etoposide 100mg and Oxaliplatin 10mg, but on … biopsy of left lung tumor. Pathological Result: … Small Cell Lung Cancer
Small cell lung cancer’s rapid … lung cancer, particularly in small-cell lung cancer patients.
The role of immunotherapy in lung cancer …
-
GenFleet Therapeutics Announces FDA's Clinical Trial Approval for GFH925 (KRAS G12C Inhibitor) Monotherapy in Phase III Registrational Study Treating Metastatic Colorectal Cancer
19 Apr 2024 12:46 GMT
… advanced non-small cell lung cancer(NSCLC)patients with G12C … combination of fluoropirimidines plus oxaliplatin or irinotecan, associated to … hot tumors such as lung cancer; more targeted agents with … cancer, and 15-20% lung cancer patients. The occurrence of …